Find, compare & contact
Technetium Tc-99m exametazime
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Technetium Tc-99m exametazime API 99944-78-2?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Technetium Tc-99m exametazime. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Technetium Tc-99m exametazime
- Synonyms:
- (99m)Tc HM-PAO , (99m)Tc HMPAO , [(99m)Tc] HM-PAO , Technetium (99mTc) exametazime , Technetium (99mTc) HMPAO , Technetium tc 99m exametazime , Technetium tc 99m HMPAO , Technetium Tc-99m exametazime
- Cas Number:
- 99944-78-2
- DrugBank number:
- DB09163
- Unique Ingredient Identifier:
- 3B744AG22N
General Description:
Technetium Tc-99m exametazime, identified by CAS number 99944-78-2, is a notable compound with significant therapeutic applications. Technetium Tc-99m exametazime is a radiopharmaceutical sold under the trade name Ceretec used in the detection of altered regional cerebral perfusion in stroke and other cerebrovascular diseases. It can also be used for the labelling of leukocytes to localise intra-abdominal infections and inflammatory bowel disease. Exametazime, also known as hexamethylpropyleneamine oxime or HMPAO, acts as a chelating agent for the Tc-99m radioisotope.
Indications:
This drug is primarily indicated for: Technetium Tc99m exametazime scintigraphy (with or without methylene blue stabilization) may be useful as an adjunct in the detection of altered regional cerebral perfusion in stroke. Tc99m exametazime without methylene blue stabilization is indicated for leukocyte labeled scintigraphy as an adjunct in the localization of intra-abdominal infection and inflammatory bowel disease. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Absorption:
The absorption characteristics of Technetium Tc-99m exametazime are crucial for its therapeutic efficacy: Technetium Tc-99m exametazime is rapidly cleared from the blood after intravenous injection. Uptake in the brain reaches a maximum of 3.5-7.0% of the injected dose within one minute of injection. Up to 15% of the activity is eliminated from the brain by 2 minutes post injection, after which little activity is lost for the following 24 hours except by physical decay of technetium Tc99m. The drug's ability to rapidly penetrate into cells ensures quick onset of action.
Route of Elimination:
The elimination of Technetium Tc-99m exametazime from the body primarily occurs through: About 30% of the injected dose is found in the gastrointestinal tract immediately after injection and about 50% of this is excreted through the intestinal tract over 48 hours. Also, about 40% of the injected dose is excreted through the kidneys and urine over the 48 hours after injection. Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.
Volume of Distribution:
Technetium Tc-99m exametazime is distributed throughout the body with a volume of distribution of: The activity not associated with the brain is widely distributed throughout the body, particularly in muscle and soft tissue. This metric indicates how extensively the drug permeates into body tissues.
Pharmacodynamics:
Technetium Tc-99m exametazime exerts its therapeutic effects through: During the first hour following injection of Tc99m labeled leukocytes, activity is seen in the lungs, liver, spleen, blood pool, bone marrow and the bladder. The kidneys (parenchyma and/or renal pelvis) and gall bladder may also be visualized. Over the first 1-6 hours, the Tc99m is visualized in the bowel. At 24 hours post-injection substantial colonic activity is seen. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.
Categories:
Technetium Tc-99m exametazime is categorized under the following therapeutic classes: Amines, Central Nervous System, Compounds used in a research, industrial, or household setting, Diagnostic Radiopharmaceuticals, Diagnostic Uses of Chemicals, Drugs that are Mainly Renally Excreted, Hydroxylamines, Indicators and Reagents, Laboratory Chemicals, Organometallic Compounds, Organotechnetium Compounds, Oximes, Radioactive Diagnostic Agent, Radiopharmaceutical Activity, Radiopharmaceuticals, Technetium (99Mtc) Compounds. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Technetium Tc-99m exametazime is a type of Central Nervous System Agents
Central Nervous System (CNS) Agents are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that specifically target the central nervous system. The CNS encompasses the brain and spinal cord, playing a vital role in regulating and controlling various bodily functions, including cognition, movement, emotions, and sensory perception. These agents are designed to interact with specific receptors, enzymes, or ion channels within the CNS to modulate neural activity and restore normal functioning.
CNS agents comprise a diverse range of pharmaceutical APIs, including analgesics, anesthetics, antipsychotics, sedatives, hypnotics, anti-epileptics, and antidepressants. Each subcategory addresses distinct neurological disorders and conditions. For instance, analgesics alleviate pain by targeting receptors in the brain and spinal cord, while antipsychotics are employed to manage psychosis symptoms in mental illnesses such as schizophrenia.
The development of CNS agents involves rigorous research, molecular modeling, and extensive clinical trials to ensure safety, efficacy, and specific target engagement. Pharmaceutical companies invest significant resources in identifying novel drug targets, synthesizing new compounds, and optimizing their pharmacological properties. These agents undergo rigorous regulatory evaluations and must adhere to stringent quality standards and guidelines.
Given the prevalence of CNS disorders globally, the market demand for effective CNS agents is substantial. The development of innovative CNS APIs not only improves patient outcomes but also provides valuable commercial opportunities for pharmaceutical companies. Continued advancements in CNS agent research and development hold the promise of groundbreaking therapies that can improve the quality of life for individuals affected by neurological conditions.
